Manosrin A New Hypoglycaemic Compound From Anisopus Mannii N.E.Br.

The aqueous extracts of ten selected herbal traditional medicinal plants namely Catunaregam tormentosa Raulfia serpentine Moringa oleifera and Anisopus mannii among others from the North Eastern Nigeria were screened ab initio in albino mice n 5 using standard procedures. The fraction with the highest hypoglycaemic activity was later extracted with 80 vv MeOH using soxhlet extractor. The crude MeOH extract was partitioned with CHCl3 and other solvents after TLC and sub-fractions obtained were tested in diabetic mice n 5 using standard procedures to ascertain the most potent hypoglycaemic sub-fraction. This was further purified using HPLC and tested on diabetic mice n 5 with doses ranging from 1 to 1000 folds gkg bw and compared to standards drugs Glibenclamide and Insulin respectively. The sub-fraction was characterized using 1H and 13C - NMR and two-dimensional correlation spectroscopy COSY NOESY HMQC and HMBC. A new compound 3 23 28Trihydroxy-12-oleanen-3-O--D-glucopyranosyl-16--D-glucopyranosyl-16--D-xylopyranosyl-28-O--D-glucopyranosyl-16--D-glucopyranoside Manosrin was obtained after characterization. Manosrin showed 45.15 and 67.97 hypoglycaemic effect with 10 and 100 N folds dosages respectively. The observed effects were almost at par with the standard drugs. The discovery of Manosrin from A. mannii N. E. Br. is as a new compound will add to the already existing list of known pharmaceutical hypoglycaemic compounds and a new development in the management of diabetes mellitus. Studies on toxicity mechanism of Manosrin action will be published soon.